Anticoagulant response to agkistrodon contortrix venom (ACV test): A new global test to screen for defects in the anticoagulant protein C pathway

Thrombosis and Haemostasis

Volumn 75, Issue 4, 1996, Pages 562-566

  Robert, A ^a   Eschwege V ^a   Hameg, H ^a   Drouet, L ^b   Aillaud, M F ^c  

^a HÔPITAL SAINT ANTOINE   (France)

^b Laboratoire Central d'Hematologie   (France)

^c TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5; PROTAC; PROTEIN C; SNAKE VENOM; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; HUMAN; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; SCREENING TEST;

EID: 0029990105     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650322     Document Type: Article

References (35)

1. Gladson CL, Scharrer I, Hack V, Beck KH, Griffin JH. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988; 59: 18-22.
2. Ben-Tal O, Zivelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophiha in Israel. Thromb Haemost 1989; 61: 50-4.
3. Tabernero MD, Thomas JF, Alberca I, Orfao A, Borrasca AL, Vicente V Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis Am J Hematol 1991; 36: 249-54.
4. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
5. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7
6. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln in factor Va. Lancet 1994; 343: 1362
7. 506 of factor V. Lancet 1994; 343: 1535-6.
8. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-8.
9. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.
10. Griffin JH, Evan B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood 1993; 82: 1989-93.
11. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-6
12. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22
13. Cadroy Y, Sié P, Boneu B. Frequency of a defective response to activated protein C in patients with a history of venous thrombosis. Blood 1994; 83: 2008-9.
14. Halmayer WM, Haushofer A, Schön R, Fischer M. The prevalence of poor anucoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coag Fibrinol 1994; 5: 51-7.
15. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
16. Pabinger I, Allaart CF, Hermans J, Briet E, Bertina RM and the Protein C Transmitter Study Group. Hereditary protein C-deficiency: Laboratory values in transmitters and guidelines for the diagnostic procedure. Report on a study of the SSC Subcommittee on protein C and protein S. Thromb Haemost 1992; 68: 4704.
17. Boyer-Neumann C, Bertina RM, Tripodi A, D'Angelo A, Wolf M, Vigano D'Angelo S, Mannucci PM, Meyer D, Larrieu MJ. Comparison of functional assays for protein S: European collaborative study of patients with congenital and acquired deficiency. Thromb Haemost 1993; 70: 946-50.
18. Fatoni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay Thromb Haemost 1993; 70: 1067-71.
19. de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria Thromb Haemost 1994; 72: 880-6.
20. Stocker K, Fischer H, Meier J, Brogli M, Svendsen L. Characterization of the protein C activator Protac* from the venom of the southern copperhead (Agkistrodon Contortrix) snake. Toxicon 1987; 25: 239-52.
21. Exner T, Vaasjoki R. Characterisation and some properties of the protein C activator from Agkistrodon Contortrix Contortrix venom Thromb Haemost 1988; 59: 40-4.
22. Kraus M, Noah M, Fickenscher K. The PCAT - A simple screening assay for assessing the functionality of the protein C anticoagulant pathway. Thromb Res 1995; 79: 217-22.
23. Reed AH, Henry RJ, Mason WB. Influence of statistical method used on the resulting estimate of normal range. Clin Chem 1971; 17: 275-84.
24. Martinolli JL, Stocker K. Fast functional protein C assay using Protac®, a novel protein C activator Thromb Res 1986; 43: 253-64.
25. Nathan IV, Han Ping, MM Pradhan. Protein C functional assay using snake venom activator. Thromb Res 1987; 43: 253-64.
26. Suzuki K, Nishioka J Plasma protein S activity using Protac, a snake venom derived activator of protein C. Thromb Res 1988; 49: 241-51.
27. 506-factor V. Blood 1995; 85: 3405-11.
28. 506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons. Thromb Haemost 1995; 73: 739-42.
29. Koedam JA, Meijers JCM, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82: 1236-40.
30. Bertina R, Reitsma PH, Rosendaal FR, Vaadenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995; 74: 449-53.
31. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurence of deep-vein thrombosis. Lancet 1995; 345: 152-55.
32. Trossaert M, Conard J, Horellou MH, Samama MM. Influence of storage conditions on activated protein C resistance assay. Thromb Haemost 1995; 73: 163-4.
33. Rosen S, Johansson K, Lindberg K, Dahlbäck B. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. Thromb Haemost 1994; 72: 255-60.
34. Henkens CMA, Bom VJJ, Seinen AJ, van der Meer J. Sensitivity to activated protein C: Influence of oral contraceptives and sex. Thromb Haemost 1995; 73: 402-4.
35. Tait RC, Walker ID, Islam SIAM, McCall F, Conkie JA, Wight M, Mitchell R, Davidson JF. Protein C activity in healthy volunteers - Influence of age, sex, smoking and oral contraceptive. Thromb Haemost 1993; 70: 281-5